Fennec Pharmaceuticals (FENC) Return on Capital Employed (2011 - 2025)
Fennec Pharmaceuticals (FENC) posted Return on Capital Employed of 12.72% for Q4 2025, down 1.64% on a QoQ basis from 12.52% in Q3 2025, and down 1843.0% year-over-year from 0.73% in Q4 2024.
Fennec Pharmaceuticals (FENC) Return on Capital Employed (2011 - 2025) Analysis & Trends
Fennec Pharmaceuticals' Return on Capital Employed history runs 15 years deep, the most recent figure standing at 12.72% for Q4 2025.
- Quarterly Return on Capital Employed fell 1843.0% year-over-year to 12.72% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 12.72% (down 1843.0% YoY) and the FY2025 annual result came in at 13.3%, down 2216.0% from the prior year.
- Return on Capital Employed was 12.72% for Q4 2025 at Fennec Pharmaceuticals, down from 12.52% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 16.34% in Q1 2024 and bottomed at 142.25% in Q2 2023.
- A 5-year average of 58.88% and a median of 68.76% in 2021 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed plunged 5171 bps — and 2024, when it soared 15229 bps.
- Fennec Pharmaceuticals' Return on Capital Employed stood at 76.34% in 2021, then fell by 23 bps to 93.85% in 2022, then advanced by 14 bps to 80.48% in 2023, then soared by 107 bps to 5.7% in 2024, then slumped by 323 bps to 12.72% in 2025.
- Business Quant data shows FENC's Return on Capital Employed at 12.72% in Q4 2025, 12.52% in Q3 2025, and 25.99% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -68.84% |
| 10 | Fennec Pharmaceuticals | 287.77 Mn | 250.98 Mn | 12.01 Mn | -12.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12.72% |
| Sep 30, 2025 | -12.52% |
| Jun 30, 2025 | -25.99% |
| Mar 31, 2025 | -32.12% |
| Dec 31, 2024 | 5.70% |
| Sep 30, 2024 | 3.14% |
| Jun 30, 2024 | 10.04% |
| Mar 31, 2024 | 16.34% |
| Dec 31, 2023 | -80.48% |
| Sep 30, 2023 | -108.19% |
| Jun 30, 2023 | -142.25% |
| Mar 31, 2023 | -119.42% |
| Dec 31, 2022 | -93.85% |
| Sep 30, 2022 | -102.97% |
| Jun 30, 2022 | -118.25% |
| Mar 31, 2022 | -84.99% |
| Dec 31, 2021 | -76.34% |
| Sep 30, 2021 | -65.32% |
| Jun 30, 2021 | -66.54% |
| Mar 31, 2021 | -70.98% |